Jackson Walker L.L.P. successfully represented Repros Therapeutics Inc. (Nasdaq: RPRX) in an underwritten public offering of common stock, which closed on June 25, 2013.
Repros Therapeutics offered 4.31 million shares of its common stock at a public offering price of $19 per share, for net proceeds of approximately $76.5 million after the deduction of underwriting discounts and other estimated offering expenses.
The Woodlands, Texas-based biopharmaceutical company will use the proceeds from this offering to further the clinical development of its Androxal® and Proellex® drug programs and for general administrative purposes.
A Jackson Walker team led by Jeff Harder and including Steve Jacobs, Marisela Peña Gonzalez, Ron Kerridge and Joe Fonlon represented Repros Therapeutics in the transaction. Attorneys in Jackson Walker’s Corporate & Securities practice group are skilled in providing uniquely tailored and highly responsive representation to public companies in a wide variety of complex matters.